Birchview Capital LP Has $705,000 Stock Position in Xenon Pharmaceuticals Inc. $XENE

Key Points

• Birchview Capital LP increased its stake in Xenon Pharmaceuticals by 110.0% during the 1st quarter, bringing its total ownership to $705,000.
• Institutional investors own 95.45% of Xenon Pharmaceuticals, indicating strong institutional interest in the company.
• Xenon Pharmaceuticals reported a quarterly EPS of (1.07), missing expectations, and analysts forecast a full-year EPS of (3.10).

Birchview Capital LP lifted its holdings in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 110.0% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm owned 21,000 shares of the biopharmaceutical company's stock after buying an additional 11,000 shares during the period. Xenon Pharmaceuticals makes up approximately 0.6% of Birchview Capital LP's holdings, making the stock its 27th largest position. Birchview Capital LP's holdings in Xenon Pharmaceuticals were worth $705,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently added to or reduced their stakes in XENE. GF Fund Management CO. LTD. grew its holdings in Xenon Pharmaceuticals by 21.9% in the 1st quarter. GF Fund Management CO. LTD. now owns 1,952 shares of the biopharmaceutical company's stock valued at $65,000 after buying an additional 351 shares during the period. Natixis Advisors LLC grew its holdings in Xenon Pharmaceuticals by 1.9% in the first quarter. Natixis Advisors LLC now owns 24,010 shares of the biopharmaceutical company's stock valued at $806,000 after purchasing an additional 456 shares during the period. Occudo Quantitative Strategies LP increased its position in Xenon Pharmaceuticals by 5.8% during the fourth quarter. Occudo Quantitative Strategies LP now owns 11,441 shares of the biopharmaceutical company's stock worth $448,000 after purchasing an additional 630 shares during the last quarter. Caitong International Asset Management Co. Ltd acquired a new position in Xenon Pharmaceuticals during the first quarter worth approximately $30,000. Finally, Vident Advisory LLC raised its stake in Xenon Pharmaceuticals by 21.4% during the first quarter. Vident Advisory LLC now owns 6,574 shares of the biopharmaceutical company's stock worth $221,000 after purchasing an additional 1,161 shares during the period. Institutional investors and hedge funds own 95.45% of the company's stock.

Analyst Ratings Changes

A number of analysts recently issued reports on the stock. Royal Bank Of Canada reissued an "outperform" rating and set a $55.00 target price on shares of Xenon Pharmaceuticals in a research report on Tuesday. Evercore ISI assumed coverage on shares of Xenon Pharmaceuticals in a research note on Wednesday, May 14th. They issued an "outperform" rating and a $55.00 target price on the stock. Chardan Capital reaffirmed a "buy" rating and set a $55.00 price target on shares of Xenon Pharmaceuticals in a research report on Tuesday, August 12th. Wall Street Zen downgraded Xenon Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Wednesday, May 21st. Finally, Wells Fargo & Company initiated coverage on Xenon Pharmaceuticals in a report on Wednesday. They set an "overweight" rating and a $48.00 target price on the stock. Eleven analysts have rated the stock with a Buy rating, According to MarketBeat, the stock has an average rating of "Buy" and an average target price of $53.30.

Xenon Pharmaceuticals Trading Up 1.5%

Xenon Pharmaceuticals stock traded up $0.57 during midday trading on Friday, hitting $39.21. The stock had a trading volume of 646,087 shares, compared to its average volume of 881,429. The business has a fifty day moving average price of $34.52 and a 200 day moving average price of $33.96. Xenon Pharmaceuticals Inc. has a 12 month low of $26.74 and a 12 month high of $46.00. The stock has a market cap of $3.02 billion, a P/E ratio of -11.05 and a beta of 1.17.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last posted its earnings results on Monday, August 11th. The biopharmaceutical company reported ($1.07) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.03) by ($0.04). During the same quarter in the prior year, the company posted ($0.75) earnings per share. On average, equities analysts anticipate that Xenon Pharmaceuticals Inc. will post -3.1 EPS for the current fiscal year.

Xenon Pharmaceuticals Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.